Literature DB >> 10596033

Neutropenia in patients with HIV infection: a case control study in a cohort of 1403 patients between 1982 and 1993.

P Hermans1, B Sommereijns, N Van Cutsem, N Clumeck.   

Abstract

The relationship between neutropenia and increased risks of severe infections in patients with HIV infection and the factors associated with neutropenia-induced infections was studied by a retrospective comparative study using matched case-control analysis. A database (1982-1993) of 1870 patients with HIV infection was searched, and from 484 patients with neutropenia, 177 patients were paired with 177 nonneutropenic control subjects. Descriptive analysis and development of logistic models were used to determine factors associated with the risk of developing bacterial infections and major fungal infections. The occurrence of severe bacterial and fungal infections was significantly higher in neutropenic patients (p < or = 0.001). Bacteremia was more common in neutropenic patients than in nonneutropenic patients (p < or = 0.02) in the matched case-control analysis. Risk of severe infections was strongly associated with the neutrophil count (p < or = 0.05), clinical stage, and hemoglobin level (p < 0.005) when paired patients were compared. More neutropenic episodes occurred between 1991 to 1993, possibly due to prolonged survival and the increasing use of concomitant myelosuppressive therapies. Neutropenic HIV-infected patients are significantly at risk of developing severe infections at the end-stage of HIV disease, and this may have a major impact on hospitalization and death. Preventing neutropenia could dramatically improve the quality of life of these patients.

Entities:  

Mesh:

Year:  1999        PMID: 10596033     DOI: 10.1089/152581699319894

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  6 in total

Review 1.  Filgrastim in patients with neutropenia: potential effects on quality of life.

Authors:  Gary H Lyman; Nicole M Kuderer
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

3.  The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry.

Authors:  Hemant Kulkarni; Vincent C Marconi; Weijing He; Michael L Landrum; Jason F Okulicz; Judith Delmar; Dickran Kazandjian; John Castiblanco; Seema S Ahuja; Edwina J Wright; Robin A Weiss; Robert A Clark; Matthew J Dolan; Sunil K Ahuja
Journal:  Blood       Date:  2009-07-20       Impact factor: 22.113

4.  Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Authors:  Thomas B Campbell; Laura M Smeaton; N Kumarasamy; Timothy Flanigan; Karin L Klingman; Cynthia Firnhaber; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Umesh Lalloo; Cynthia Riviere; Jorge Sanchez; Marineide Melo; Khuanchai Supparatpinyo; Srikanth Tripathy; Ana I Martinez; Apsara Nair; Ann Walawander; Laura Moran; Yun Chen; Wendy Snowden; James F Rooney; Jonathan Uy; Robert T Schooley; Victor De Gruttola; James Gita Hakim
Journal:  PLoS Med       Date:  2012-08-14       Impact factor: 11.069

5.  Incidence of Severe Neutropenia in HIV-Infected People Starting Antiretroviral Therapy in West Africa.

Authors:  Charline Leroi; Eric Balestre; Eugene Messou; Albert Minga; Adrien Sawadogo; Joseph Drabo; Moussa Maiga; Marcel Zannou; Moussa Seydi; Francois Dabis; Antoine Jaquet
Journal:  PLoS One       Date:  2017-01-25       Impact factor: 3.240

6.  Prevalence and Risk Factors of Cytopenia in HIV-Infected Patients before and after the Initiation of HAART.

Authors:  Lina Fan; Cuilin Li; Hongxin Zhao
Journal:  Biomed Res Int       Date:  2020-01-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.